Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2801-2805 | ISSN:2251-6727

"Metabolic Alterations in Chronic Kidney Disease Patients: A Comprehensive Biochemical Analysis."

Mr.Kiran S.Suryawanshi 1, , Dr. Nitin S. Nagane 2, Mr.Vinayak B. Mane 3 Dr.R.B. Kulkarni 4.Dr. Asma Devale 5.

1) Tutor in Biochemistry Dept. Bharati Vidyapeeth (Deemed To Be University) Medical College and Hospital Sangli.

2) professor in Biochemistry Dept. Bharati Vidyapeeth (Deemed To Be University) Medical College and Hospital Sangli.

3) Tutor in Biochemistry Dept. Bharati Vidyapeeth (Deemed To Be University) Medical College and Hospital Sangli.

4) professor in Dept of Medicine . Bharati Vidyapeeth (Deemed To Be University) Medical College and Hospital Sangli.

5) professor and Head in Biochemistry Dept. Bharati Vidyapeeth (Deemed To Be University) Medical College and Hospital Sangli.

(Received: 07 January 2024 Revised: 12 February 2024 Accepted: 06 March 2024)

KEYWORDS

Chronic Kidney Disease, CKD-MBD, Biochemical Analysis, Bone Health, Personalized Care.

ABSTRACT:

Introduction Chronic Kidney Disease (CKD) is a global health concern affecting millions of individuals, with a disproportionate impact on developing nations. Renal replacement therapies, such as kidney transplants, hemodialysis, and peritoneal dialysis, play a crucial role in saving lives but contribute significantly to healthcare spending. This research paper presents a comprehensive study conducted at the Department of Biochemistry, Bharati Vidyapeeth (Deemed To Be University) Medical College and Hospital Sangli, focusing on the evolution of metabolic alterations in bones causing abnormal bone homeostasis in CKD patients..Objectives: The primary objective of this study is to conduct a stage-wise biochemical analysis of CKD patients, examining key parameters related to metabolic alterations in bones, including blood urea, serum creatinine, calcium, phosphorous, iPTH, vit.D3, alkaline phosphatase, and osteocalcin. The study aims to provide valuable insights into the interconnectedness of abnormal mineral metabolism, bone health, and extraskeletal problems, with a focus on age, gender, dialysis specifics, medication use, surgical interventions, co-morbidities, and dietary changes.

Methods: The study enrolled a cohort of CKD patients, and their biochemical parameters were analyzed at different stages of the disease progression. The parameters were measured using standardized laboratory techniques. Statistical analyses were performed to identify correlations and significant associations.

Results: The study observed a highly significant elevation and positive correlation ($p<0.001$) of blood urea and serum creatinine in CKD patients, emphasizing their utility as markers for disease progression. Significant lowering of serum calcium levels ($p<0.004$) was noted, primarily attributed to hypovitaminosis D and reduced kidney capacity to release active vitamin D3. Furthermore, a significant elevation of serum phosphorous levels ($p<0.009$) was identified, indicating progressive hyperphosphatemia associated with CKD.

Conclusions: This research sheds light on the complex interplay of factors in CKD-MBD, emphasizing the implications for bone health and cardiovascular disease. The stage-wise

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2801-2805 | ISSN:2251-6727

biochemical analysis provides valuable insights for clinicians in managing CKD patients at different disease stages, guiding personalized and effective care strategies.

1. Introduction

Chronic Kidney Disease (CKD) represents a significant global health challenge affecting millions of individuals, necessitating renal replacement therapies such as kidney transplants, hemodialysis, and peritoneal dialysis for life-saving interventions. However, the escalating costs associated with these treatments pose a substantial burden on healthcare spending, prompting the need for a deeper understanding of CKD and its complications.

CKD exhibits a higher prevalence in developing nations compared to wealthy countries, with systemic hypertension, diabetic nephropathy, and chronic glomerulonephritis identified as the predominant causes. As the global population ages, the incidence of CKD rises exponentially, particularly affecting individuals in older age groups, where the prevalence is 10 times higher compared to those between 20 and 40 years. This surge may be attributed to the increasing prevalence of conditions such as hypertension and diabetes, which are known precursors to CKD.

Among the myriad complications associated with CKD, bone disorders, including osteoporosis, stand out as one of the most common. Osteoporosis in CKD patients necessitates a comprehensive investigation into the metabolic alterations within bones, unraveling the abnormal bone homeostasis that characterizes CKD-Mineral and Bone Disorder (CKD-MBD).

The present study, conducted at the Department of Biochemistry, Bharati Vidyapeeth (Deemed To Be University) Medical College and Hospital Sangli, delves into the evolution of metabolic alterations in bones, seeking to elucidate abnormal bone homeostasis in CKD patients. A range of project parameters, including blood urea, serum creatinine, calcium, phosphorous, and alkaline phosphatase, were systematically estimated. The values obtained were analyzed in comparison with the progression of CKD, providing valuable insights into the biochemical changes associated with this complex condition.

This research aims to contribute to the existing body of knowledge on CKD-MBD, offering a detailed exploration of biochemical markers that can aid in understanding disease progression. By identifying key parameters associated with bone health, this study seeks to provide a foundation for more targeted and effective interventions in CKD patients, ultimately improving patient outcomes and reducing the economic burden associated with CKD treatment.

Objectives

The primary objective of this research is to conduct a comprehensive stage-wise biochemical analysis of patients with Chronic Kidney Disease (CKD), focusing on key parameters associated with metabolic alterations in bones. The study aims to provide valuable insights into the interconnected relationships among abnormal mineral metabolism, bone health, and extraskeletal complications, considering various influencing factors such as age, gender, dialysis specifics, medication use, surgical interventions, co-morbidities, and dietary changes.

Evaluate Blood Urea and Serum Creatinine Levels:

Analyze the stage-wise variations in blood urea and serum creatinine levels in CKD patients.

Establish correlations between these parameters and their significance in indicating disease progression.

Examine Calcium and Phosphorous Levels:

Investigate the fluctuations in serum calcium and phosphorous levels throughout different stages of CKD.

Identify the impact of altered homeostasis on calcium metabolism and phosphorous clearance in CKD patients.

Assess Alkaline Phosphatase Activity:

Evaluate the activity of alkaline phosphatase in relation to CKD stages.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2801-2805 | ISSN:2251-6727

Examine the potential implications of elevated alkaline phosphatase in bone metabolism and CKD-Mineral and Bone Disorder (CKD-MBD).

Explore Interconnected Factors:

Investigate the interconnectedness of abnormal mineral metabolism with bone health and extraskeletal manifestations in CKD.

Analyze the influence of age and gender on biochemical markers and disease progression.

Consider Dialysis Specifics and Medication Impact:

Assess the impact of different dialysis modalities on the biochemical parameters studied.

Investigate the influence of medications on metabolic alterations and bone homeostasis in CKD patients.

2. Methods

Study Design: This research adopted a prospective cohort study design to investigate the biochemical parameters of patients with Chronic Kidney Disease (CKD) at different stages of disease progression.

Participants: The study enrolled a representative cohort of CKD patients from the Department of Biochemistry, Bharati Vidyapeeth (Deemed To Be University) Medical College and Hospital Sangli. Informed consent was obtained from all participants, and ethical approval was secured from the Institutional Review Board.

Inclusion Criteria:

Confirmed diagnosis of CKD.

Willingness to participate and provide informed consent.

Exclusion Criteria:

Presence of other significant comorbidities affecting biochemical parameters.

Inability to provide informed consent.

Data Collection:

Biochemical Parameters:

Blood Urea and Serum Creatinine: Analyzed using standard laboratory techniques such as enzymatic assays.

Calcium and Phosphorous: Measured through automated chemistry analyzers.

Alkaline Phosphatase: Assessed using colorimetric assays.

Disease Staging:

CKD staging was determined based on estimated glomerular filtration rate (eGFR) and severity of renal impairment.

Statistical Analysis:

Data were analyzed using appropriate statistical tools, including ANOVA or Kruskal-Wallis tests for comparison between multiple groups.

Correlation analyses (e.g., Pearson or Spearman) were employed to assess associations between biochemical parameters.

Statistical significance was set at $p < 0.05$.

Results

1. Blood Urea and Serum Creatinine:

A highly significant elevation ($p<0.001$) of both blood urea and serum creatinine was observed in CKD patients.

The positive correlation between blood urea and serum creatinine reinforces their utility as robust markers for assessing disease progression in CKD.

2. Serum Calcium Levels:

A significant reduction in serum calcium levels ($p<0.004$) was noted in CKD patients.

This decline is primarily attributed to hypovitaminosis D, indicating impaired synthesis of active vitamin D3 by damaged kidneys. The reduced capacity of the kidneys to release active vitamin D3 contributes to decreased calcium absorption and mobilization.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2801-2805 | ISSN:2251-6727

3. Serum Phosphorous Levels:

A significant elevation in serum phosphorous levels ($p<0.009$) was identified in CKD patients.

This finding suggests progressive hyperphosphatemia associated with CKD, highlighting the challenges faced by damaged kidneys in effectively removing phosphorus from the body. The compromised glomeruli and tubules in CKD contribute to the accumulation of phosphorus, leading to the formation of phosphate. The increased availability of phosphate may activate the release of alkaline phosphatase, further contributing to elevated serum phosphorous levels.

Discussion

The observed elevation in both blood urea and serum creatinine in CKD patients, with a highly significant correlation ($p<0.001$), underscores the well-established role of these markers as reliable indicators of renal dysfunction. These findings align with existing literature, emphasizing their utility in assessing disease progression and providing clinicians with valuable tools for monitoring kidney function in CKD patients.

The significant reduction in serum calcium levels ($p<0.004$) adds a layer of complexity to the CKD-Mineral and Bone Disorder (CKD-MBD). Hypovitaminosis D emerges as a crucial factor, indicating impaired synthesis of active vitamin D3 by damaged kidneys. The diminished capacity of the kidneys to release active vitamin D3 contributes to decreased calcium absorption and mobilization. This deficiency in calcium homeostasis may have implications beyond bone health, potentially impacting cardiovascular function and extraskeletal complications in CKD patients.

The significant elevation in serum phosphorous levels ($p<0.009$) highlights the progressive hyperphosphatemia associated with CKD. The compromised glomeruli and tubules in CKD contribute to the accumulation of phosphorus, leading to phosphate formation. The increased availability of phosphate may activate the release of alkaline phosphatase, further contributing to elevated serum phosphorous levels. This complex interplay between altered phosphorus metabolism and CKD-MBD emphasizes the intricate web of biochemical disturbances that manifest in patients with advanced renal dysfunction.

Clinical Implications:

The identified correlations among blood urea, serum creatinine, serum calcium, and serum phosphorous provide clinicians with valuable insights into the pathophysiology of CKD-MBD. These biochemical markers serve not only as diagnostic tools but also as indicators of the intricate interplay between mineral metabolism and bone health. Clinicians can utilize this knowledge to tailor interventions that address both renal dysfunction and associated metabolic complications, potentially improving patient outcomes and quality of life.

The reduction in serum calcium and the concomitant elevation in serum phosphorous levels reinforce the need for a holistic approach to CKD-MBD management. Strategies aimed at mitigating hypovitaminosis D and addressing challenges in phosphorous clearance should be explored. Additionally, personalized approaches to enhance bone health, beyond traditional therapies, may prove beneficial in preventing or slowing the progression of CKD-MBD.

Future Directions:

The findings presented here open avenues for further investigations into targeted interventions for managing CKD-MBD. Future studies should delve into the development of strategies to address hypovitaminosis D, exploring innovative therapies or supplementation regimens. Research should also focus on novel approaches to enhance phosphorous clearance, potentially through medications or dietary interventions.

Moreover, the correlations identified in this study offer a foundation for developing prognostic tools. Predictive models based on these biochemical markers may assist clinicians in foreseeing disease progression and tailoring treatment strategies accordingly. This personalized approach aligns with the current trend in precision medicine and could potentially improve the effectiveness of interventions, leading to better outcomes for CKD patients.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2801-2805 | ISSN:2251-6727

Refrences

1) B Thibedi[I]; EJ Raubenheimer[II]; CEE Noffke[III] Chronic kidney disease and the skeleton: Pathogenesis, complications and principles of management; BCur, MBChB. Nephrology Unit, & Internal Medicine, Medunsa Campus, University of Limpopo; METABOLIC SA orthop. j. vol.13 n.1 Pretoria Jan./Mar. 2014

2) Salvador Lopez-Giacomanand Magdalena Madero, Biomarkers in chronic kidney disease, from kidney function to kidney damage; World J Nephrol. 2015 Feb 6; 4(1): 57–73: PMC4317628

3) Hilton R. Clinical review: acute renal failure.13Mj2006;333:786-90

.4) Igor G Nikolov1,Ognen Ivanovs k2; Nobuhiko Joki3, 1,2 University clinic of Nephrology, medical faculty-Skopje, Division of Nephrology, Toho University Ohashi medical center, Tokyo;book.department@ intechopen.com,24-46.

5) KD:patient;Patient.info/doctor/chronic kidney disease pro:1-11.

6) Mosby's Dictionary of Medicine, Nursing and health professions. 7th ed. St. Louis, MO; Mosby:2006.

7) Marianne Rix,Helle Andreassen, Peter Eskildsen etal , Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure, kidney International,vol 56(1999), PP:1084-1093.

8) Kevin J. Martin and Esther A. Gonzalez, Metabolic Bone Disease in Chronic Kidney Disease : Division of Nephrology, Saint Louis University Medical Center, Division of Nephrology (9-FDT), 3635 Vista Avenue, St. Louis, MO 63110l. Phone: 314-577-8765; Fax: 314-771-0784; Martinkj@slu.edu;Journal of American Society of Nephrology.

9) Paul D Miller, Chronic Kidney disease and the skeleton, review article; Bone research 2014:2,14044; dooi:10.1038/bomers2010.44, Sichuan university .

10) Divya Pandya1, Anil Kumar Nagrajappa2, K.S.Ravi3, Original Article, Assessment and correlation of urea and creatinine levels in saliva and serum of patients with chronic kidney disease, Diabetes & hypertension- A Research study: Journal of clinical & Diagnostic Research, 2016 Oct.Vol-10(10):Zc58-Zc62:Dol:10,7860/JCDR/2016/20284,8651:58-62.

11) R.Freethi, A. Velayutha Raj, Kalavathy Ponniraivan,M. et al. 'Study of serum calcium, phosphorous and alkaline phosphatase in chronic kidney disease' Dept. of Biochemistry,Chennai medical college and research centre, Trichy. International Journal of Medical Reasearch and Health sciences,2016,5,3:49-56:ISSN no.2319-5886.

12) Vickram Tejwani and Qi Qian, Calcium regulation and bone mineral metabolism in elderly patients with CKD. Division of nephrology& dept. of Medicine, mayo clinic college of medicine, Rochester,MN 55905,USA. Nutrients 2013,5,1913-1936;doi 10.3390/nu5061913.

13) Jia-feng chang,MD, Ying-feng feng,RN, Yu-sen peng Ph.D, Shih-ping HSV. Ph.D, et al; Combined alkaline phosphatase and phosphorous levels as a predictor of mortality in maintenance-Hemodialysis patients, www.md-journal.com, Medicine,vol.93,no-18, oct.2014:1-8.